Table 1 Comparison of clinical statistics between the development cohort and the validation cohort
Clinic data | Development cohort (n = 455) | Validation cohort (n = 88) | P-value |
|---|---|---|---|
Age(year) | 61.93 ± 17.77 | 67.49 ± 14.02 | 0.006 |
Sex | 0.007 | ||
male | 295 (64.84%) | 70 (79.55%) | |
female | 160 (35.16%) | 18 (20.45%) | |
Hypertension | 0.005 | ||
No | 291 (63.96%) | 70 (79.55%) | |
Yes | 164 (36.04%) | 18 (20.45%) | |
Diabetes | 0.326 | ||
No | 372 (81.76%) | 68 (77.27%) | |
Yes | 83 (18.24%) | 20 (22.73%) | |
Tumors | < 0.001 | ||
No | 439 (96.48%) | 54 (61.36%) | |
Yes | 16 (3.52%) | 34 (38.64%) | |
CRP(mg/L) | 104.84 ± 70.29 | 134.21 ± 92.80 | < 0.001 |
PCT(ng/ml) | 10.41 ± 24.61 | 7.22 ± 21.67 | 0.001 |
Neutrophils(10^9/L) | 12.26 ± 7.12 | 11.18 ± 5.58 | 0.181 |
Lymphocytes(10^9/L) | 1.07 ± 0.92 | 0.72 ± 1.00 | 0.002 |
Fibrinogen(g/L) | 4.68 ± 1.97 | 4.63 ± 1.53 | 0.818 |
D-dimer(mg/L) | 8.07 ± 9.56 | 1.78 ± 3.45 | < 0.001 |
Urea nitrogen(mmol/L) | 15.77 ± 11.37 | 309.05 ± 176.72 | < 0.001 |
Total bilirubin(umol/L) | 29.30 ± 46.29 | 16.39 ± 10.20 | 0.010 |
Albumin(g/L) | 33.56 ± 6.18 | 28.93 ± 5.10 | < 0.001 |
Blood glucose(mmol/L) | 11.63 ± 5.24 | 9.89 ± 4.39 | 0.004 |
Blood lactate(mmol/L) | 4.85 ± 12.33 | 3.59 ± 6.75 | 0.354 |
PaCO2(mmHg) | 45.43 ± 15.63 | 48.78 ± 24.64 | 0.099 |
PaO2/FiO2 | 247.17 ± 96.46 | 144.99 ± 53.66 | < 0.001 |
Shock | < 0.001 | ||
No | 178 (39.12%) | 57 (64.77%) | |
Yes | 277 (60.88%) | 31 (35.23%) | |
APACHE II score | 21.83 ± 8.36 | 21.77 ± 7.30 | 0.950 |
SOFA score | 8.37 ± 3.99 | 6.60 ± 2.73 | < 0.001 |
ICU MV time(day) | 7.49 ± 10.40 | 5.83 ± 5.10 | 0.145 |
Glucocorticoids | 0.016 | ||
No | 197 (43.30%) | 26 (29.55%) | |
Yes | 258 (56.70%) | 62 (70.45%) | |
Death | 0.769 | ||
No | 358 (78.68%) | 68 (77.27%) | |
Yes | 97 (21.32%) | 20 (22.73%) |